Abiopharma

EDAP TMS S.A. (EDAP) Reports the reporting period Financial Results EDAP TMS S.A. (EDAP) announced its financial results for the period ending the reporting period. Key Financial Highlights:

• Revenue: $12
• Net Income: Not disclosed
• EPS: Not disclosed
• Cash and equivalents: Not disclosed
  • anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy and distribution divisions, as well as risks associated with the current worldwide inflationary environment, the uncertain worldwide economic, political and financial environment, geopolitical instability, climate change and pandemics like the COVID 19 pandemic, or other public health crises, and their related impact on our business operations, including their impacts across our businesses or demand for our devices and services. Other factors that may cause such a difference may also include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F. Forward-looking statements speak only as of the date they are made. Other than required by law, we do not undertake any obligation to update them in light of new information or future developments. These forward-looking statements are based upon information, assumptions and estimates available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete. Investor Contacts Investor Relations EDAP TMS SA investor.relations@focalone.com John Fraunces LifeSci Advisors, LLC (917) 355-2395